A new study involving an experimental drug showed improved survival in men with severe prostate cancer. Researchers say the drug may become a new way to treat patients with other hard-to-reach or inoperable cancers. The study tested a new kind of medicine called radiopharmaceuticals. These drugs deliver radiation directly to cancer cells. The drug in this case is a molecule that contains two parts: one that hunts for the cancer cells and another that kills them. Trillions of these molecules hunt down cancer cells, then they are killed by radiation. “You can treat tumors that you cannot see. Anywhere the drug can go, the drug can reach tumor cells,” said Dr. Frank Lin. He works at the National Cancer Institute helping to develop such medicine but did not take part in the study. The American Society of Clinical Oncology recently released the results of the study. The drug’s maker, Novartis, paid for the research. The company plans to seek approvals in the United States and Europe later this year. When cancer is found only in the prostate, radiation can be directed onto or inside the body. But those methods do not work well in more severe cases of prostate cancer. Each year, about 43,000 men in the United States are diagnosed with prostate cancer that has spread and no longer responds to usual treatment. The study involved 831 men with severe prostate cancer. Two-thirds were given the radiation drug, while the rest of the group were not. Patients received the drug every six weeks, up to six times. After about two years, those who received the drug did better, on average. The cancer was controlled for nearly nine months compared to about three months for the others. Survival was better, too about 15 months compared to 11 months.